Bio-Path Holdings Announced Results From Interim Analysis Of Phase 2 Clinical Trial Of Prexigebersen In Acute Myeloid Leukemia
Portfolio Pulse from Charles Gross
Bio-Path Holdings, Inc. (NASDAQ:BPTH) has reported interim data from Stage 2 of its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML). The drug has shown compelling efficacy results in two reporting cohorts, exceeding outcomes with frontline therapy.
August 01, 2023 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Path's interim data from its Phase 2 study of prexigebersen shows promising results, which could potentially boost investor confidence in the company.
The reported interim data shows that prexigebersen, Bio-Path's drug for AML treatment, has shown compelling efficacy results. This positive news could potentially increase investor confidence in the company and its product, leading to a potential increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100